Mission Statement, Vision, & Core Values (2026) of PharmaBlock Sciences (Nanjing), Inc.

As a global, fully integrated CRDMO traded on the Shenzhen Stock Exchange under 300725.SZ, PharmaBlock Sciences (Nanjing) Inc. fuses a clear corporate mission-accelerating drug discovery with innovative chemistry and low-carbon manufacturing-with an ambitious vision to lead in all-natural performance materials, supporting partners from discovery to commercial GMP supply across R&D and manufacturing hubs in Nanjing, Zhejiang, and Shandong; founded in 2008, the company now partners with nearly all of the top 20 pharmaceutical firms and hundreds of biotech companies worldwide, reported revenue of 1.73 billion CNY in 2023 with an annual growth of 8.18%, and embeds sustainability into operations via certifications like ISO 50001, while its core values-innovation, integrity, cooperation, tolerance, and responsibility-drive advances in process R&D, analytical development, and low-carbon GMP manufacturing that aim to move new molecules to market faster.

PharmaBlock Sciences , Inc. (300725.SZ) - Intro

• Founded: 2008
• Listing: Shenzhen Stock Exchange - 300725.SZ
• Core footprint: Nanjing, Zhejiang, Shandong (R&D + manufacturing)
• Service scope: discovery building blocks, process R&D, analytical development, GMP manufacturing
• Client base: partnerships with nearly all top 20 pharma companies and hundreds of biotech firms globally

• Deliver integrated, high-quality chemistry and manufacturing solutions that accelerate drug development timelines for partners worldwide.
• Advance low-carbon, resource-efficient production methods to reduce lifecycle emissions in pharmaceutical manufacturing.
• Maintain regulatory-grade quality and technical excellence across discovery to commercial supply.

• To be the leading global CRDMO for complex chemistry and sustainable pharmaceutical manufacturing, enabling faster patient access to new medicines.
• To embed decarbonization and circularity into standard practice across the drug development value chain.

• Science-led innovation - prioritize rigorous chemistry and process development to solve complex synthetic challenges.
• Quality & compliance - GMP, analytical robustness, and regulatory readiness at every stage.
• Sustainability - continuous improvement in energy, water, and waste performance (ISO 50001 certified energy management).
• Customer partnership - long-term collaborations with top-tier pharma and biotech, aligning capabilities to partner pipelines.
• Integrity & safety - uphold ethical standards, workplace safety, and environmental stewardship.

• ISO 50001 certification for energy management supports measurable reductions in energy intensity.
• Active initiatives to align operations with global sustainable development goals, including energy efficiency, emissions reduction, and waste minimization.
• Investment in process intensification, flow chemistry, and greener reagents to lower carbon intensity per kg of product.

• Integrated CRDMO model enables end-to-end support from early discovery building blocks to commercial GMP supply, shortening partner timelines and simplifying vendor management.
• Collaborates with nearly all top 20 global pharmaceutical companies and hundreds of biotech firms, reflecting deep integration in global supply chains and high recurring revenue potential.

PharmaBlock Sciences , Inc. (300725.SZ) - Overview

• Innovation in chemistry: expanding capabilities in novel building blocks, custom synthesis, and process R&D to shorten lead optimization timelines and reduce costs for clients.
• Low‑carbon technology: implementing energy‑efficiency and emissions‑reduction measures in pilot plants and commercial production to lower Scope 1/2 intensity and support customer sustainability goals.
• Partner acceleration: integrated services-medicinal chemistry, process chemistry, analytical, and API manufacturing-designed to compress discovery‑to‑IND cycles.
• Rapid market delivery: emphasis on scalable processes and regulatory readiness to move molecules from lab to clinic and commercial supply chains faster.

• R&D investment: PharmaBlock consistently targets a multi‑percent R&D intensity (R&D expense as a share of revenue) to sustain platform expansion and new service lines.
• Throughput: internal targets for synthesized new chemical entities (NCEs) and delivered intermediates aim to increase year‑over‑year capacity while reducing lead time per project.
• Carbon goals: adoption of low‑carbon manufacturing steps and utility upgrades with the objective of lowering energy consumption per kg of product and reporting Scope 1/2 emissions improvements.
• Time‑to‑market: process development timelines benchmarked against industry averages to achieve faster transition from lab synthesis to GMP batches for clinical supply.

• Green chemistry integration: replacing hazardous reagents, improving atom economy and solvent recovery to reduce emissions and waste.
• Process intensification: continuous flow and telescoped sequences adopted in pilot runs to shorten timelines and lower per‑unit carbon footprint.
• Partnership model: collaborative programs with biotech and big pharma clients, providing milestone‑driven services that align incentives to bring candidates into clinic faster.
• Quality and compliance: expanding GMP suites and regulatory support teams to ensure speed to market does not compromise quality or regulatory readiness.

PharmaBlock Sciences , Inc. (300725.SZ) - Mission Statement

• Prioritizing development of sustainable, plant- and bio-derived excipients and intermediates to meet growing eco-conscious demand in pharma supply chains.
• Investing in advanced process development and continuous manufacturing to improve yield, reduce waste, and ensure consistent performance in finished formulations.
• Scaling GMP manufacturing capacity and global distribution to serve multinational customers and contract partners.

• Scientific Rigor - rigorous analytical and process development to ensure reproducibility and regulatory readiness.
• Sustainability - prioritizing renewable feedstocks, waste minimization, and energy-efficient manufacturing.
• Customer Focus - co-development partnerships, transparent timelines, and IP-safe supply agreements.
• Quality & Compliance - adherence to GMP, ISO standards, and global regulatory expectations.
• Innovation & Agility - rapid scale-up capability and flexible process platforms for novel natural materials.

PharmaBlock Sciences , Inc. (300725.SZ) - Vision Statement

• Global leadership in integrated small-molecule discovery and development services.
• Best-in-class R&D efficiency through continuous technological innovation and digitalization.
• Trusted partner for pharma and biotech, focused on speed-to-clinic and manufacturability.
• Responsible corporate citizen minimizing environmental impact and maximizing societal value.

• Innovation - PharmaBlock consistently reinvests in new chemistry, automation, and process technologies to shorten development cycles and lower client costs. Investment and pipeline metrics demonstrate this priority through sustained R&D spending and platform expansion.
• Integrity - Transparent reporting, compliance with GMP and regulatory standards, and ethical partnerships underpin client trust and long-term contracts with multinational pharma firms.
• Cooperation - Cross-functional teams, client co-development programs, and academic collaborations accelerate problem-solving and technology transfer across discovery and manufacturing stages.
• Tolerance - A diverse workforce and inclusive policies foster creativity; global collaborations bring multiple scientific perspectives to complex molecule challenges.
• Responsibility - Environmental management systems, waste-minimization efforts, and local community engagement reflect commitments to sustainability and social impact.

• Tech Platforms - Investment in automated synthesis, flow chemistry, and computational chemistry to improve hit-to-lead and scale-up timelines.
• Service Integration - End-to-end offerings from medicinal chemistry and compound libraries to process R&D and commercial manufacturing enable one-stop project execution and higher client retention.
• Quality & Compliance - Multiple GMP-certified facilities and quality systems maintain regulatory readiness for both domestic and export markets.
• Talent & Culture - Training programs, cross-border mobility, and collaborative incentives align employee performance with innovation and ethical practice.

• Scaling modular manufacturing to translate discovery hits into GMP batches faster and more cost-effectively.
• Expanding partnerships with biotech and academic centers to co-develop novel chemistries and targets.
• Implementing digital lab management and AI-assisted design to raise R&D throughput and reproducibility.
• Enhancing ESG reporting and green chemistry adoption to reduce waste and energy per unit of output.